000 | 02263na a2200373 4500 | ||
---|---|---|---|
999 |
_c4229 _d4229 |
||
003 | PC4229 | ||
005 | 20210625062801.0 | ||
008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_aArenas Cortés, Alicia _92362 _eInstituto de Investigación i+12 |
||
100 |
_aAyala Díaz, Rosa María _91206 _eHematología y Hemoterapia |
||
100 |
_aBarrio García, Santiago _91467 _eHematología y Hemoterapia |
||
100 |
_aGallardo, Miguel _92437 _eHematología y Hemoterapia |
||
100 |
_aGarcia Martin, Rosa Maria _92438 _eAnatomía Patológica |
||
100 |
_aGilsanz Rodríguez, Florinda _91015 _eHematología y Hemoterapia |
||
100 |
_aJiménez Ubieto, Ana Isabel _922 _eHematología y Hemoterapia |
||
100 |
_aMartínez López, Joaquín _9389 _eHematología y Hemoterapia |
||
100 |
_aToldos González, Oscar _91946 _eAnatomía Patológica |
||
245 | 0 | 0 |
_aProteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. _h[artículo] |
260 |
_bMolecular cancer, _c2013 |
||
300 | _a12:142. | ||
500 | _aFormato Vancouver: Gallardo M, Barrio S, Fernández M, Paradela A, Arenas A, Toldos O et al. Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Mol Cancer. 2013 Nov 19;12:142. | ||
501 | _aPMID: 24252366 | ||
504 | _aContiene 35 referencias | ||
520 | _aJAK-STAT signaling through the JAK2V617F mutation is central to the pathogenesis of myeloproliferative neoplasms (MPN). However, other events could precede the JAK2 mutation. The aim of this study is to analyze the phenotypic divergence between polycytemia vera (PV) and essential thrombocytemia (ET) to find novel therapeutics targets by a proteomic and functional approach to identify alternative routes to JAK2 activation. Through 2D-DIGE and mass spectrometry of granulocyte protein from 20 MPN samples, showed differential expression of HSP70 in PV and ET besides other 60 proteins. Immunohistochemistry of 46 MPN bone marrow samples confirmed HSP70 expression. The median of positive granulocytes was 80% in PV (SD 35%) vs. 23% in ET (SD 34.25%). In an ex vivo model KNK437 was used as an inhibition model assay of HSP70, showed dose-dependent inhibition of cell growth and burst formation unit erythroid (BFU-E) in PV and ET, increased apoptosis in the erythroid lineage, and decreased pJAK2 signaling, as well as a specific siRNA for HSP70. These data suggest a key role for HSP70 in proliferation and survival of the erythroid lineage in PV, and may represent a potential therapeutic target in MPN, especially in PV. | ||
710 |
_9330 _aServicio de Anatomía Patológica |
||
710 |
_9297 _aServicio de Hematología y Hemoterapia |
||
710 |
_9625 _aInstituto de Investigación imas12 |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/4/pc4229.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |